O’Connor JPB., Tessyman V., Little RA., Babur M., Forster D., Latif A., Cheung S., Lipowska-Bhalla G., Higgins GS., Asselin M-C., Parker GJM., Williams KJ.

Banoxantrone (BN) hypoxia modification is replicated in U87, a xenograft model with different growth and hypoxia characteristics. U87 xenografts were less hypoxic than Calu6 xenografts. The group average ΔR1 for size matched (A) Calu6 was less than that for (B) U87 xenografts. Error bars are SEM. Significant difference between (C) group ΔR1 and (D) group MRI hypoxic volume were observed between the two tumor models. Examining the U87 xenografts further, (E) U87 Cohort reduction in MRI hypoxic fraction was seen at day 3 in treated drug tumors, relative to control tumors (Cn; white bars), with (F) U87 example segmented MRI images showing hypoxic (blue), normoxic (yellow), and necrotic (gray) tumor. G, Lower percentage of pimonidazole staining was detected in drug-treated U87 tumors at day 3, compared to controls. H, Example pimonidazole adduct formation images (×40 magnification).

Figure 4 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

O’Connor JPB., Tessyman V., Little RA., Babur M., Forster D., Latif A., Cheung S., Lipowska-Bhalla G., Higgins GS., Asselin M-C., Parker GJM., Williams KJ.

DOI

Type

Publication Date